Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, Irving Medical Center, New York, New York.
Department of Clinical Sciences and Community Health, Università degli Studi di Milano, Milan, Italy.
Am J Respir Crit Care Med. 2023 Jan 1;207(1):50-59. doi: 10.1164/rccm.202109-2208OC.
Early detection of respiratory diseases is critical to facilitate delivery of disease-modifying interventions. Extracellular vesicle-enriched microRNAs (EV-miRNAs) may represent reliable markers of early lung injury. Evaluate associations of plasma EV-miRNAs with lung function. The prospective NAS (Normative Aging Study) collected plasma EV-miRNA measurements from 1996-2015 and spirometry every 3-5 years through 2019. Associations of EV-miRNAs with baseline lung function were modeled using linear regression. To complement the individual miRNA approach, unsupervised machine learning was used to identify clusters of participants with distinct EV-miRNA profiles. Associations of EV-miRNA profiles with multivariate latent longitudinal lung function trajectories were modeled using log binomial regression. Biological functions of significant EV-miRNAs were explored using pathway analyses. Results were replicated in an independent sample of NAS participants and in the HEALS (Health Effects of Arsenic Longitudinal Study). In the main cohort of 656 participants, 51 plasma EV-miRNAs were associated with baseline lung function (false discovery rate-adjusted value < 0.05), 28 of which were replicated in the independent NAS sample and/or in the HEALS cohort. A subset of participants with distinct EV-miRNA expression patterns had increased risk of declining lung function over time, which was replicated in the independent NAS sample. Significant EV-miRNAs were shown in pathway analyses to target biological pathways that regulate respiratory cellular immunity, the lung inflammatory response, and airway structural integrity. Plasma EV-miRNAs may represent a robust biomarker of subclinical lung injury and may facilitate early identification and treatment of patients at risk of developing overt lung disease.
早期发现呼吸疾病对于实施疾病修饰干预至关重要。细胞外囊泡富集的 microRNAs(EV-miRNAs)可能是早期肺损伤的可靠标志物。评估血浆 EV-miRNA 与肺功能的相关性。前瞻性 NAS(正常老化研究)于 1996 年至 2015 年采集血浆 EV-miRNA 测量值,并于 2019 年通过每 3-5 年一次的肺量测定法进行评估。使用线性回归模型来评估 EV-miRNA 与基线肺功能的相关性。为了补充个体 miRNA 方法,使用无监督机器学习来识别具有不同 EV-miRNA 谱的参与者聚类。使用对数二项式回归模型来评估 EV-miRNA 谱与多变量潜在纵向肺功能轨迹的相关性。使用途径分析来探索显著 EV-miRNAs 的生物学功能。在独立的 NAS 参与者和 HEALS(砷纵向研究)样本中复制了结果。在主要的 656 名参与者队列中,有 51 种血浆 EV-miRNA 与基线肺功能相关(错误发现率调整值 < 0.05),其中 28 种在独立的 NAS 样本和/或 HEALS 队列中得到了复制。具有不同 EV-miRNA 表达模式的参与者子集具有随时间推移肺功能下降的风险增加,在独立的 NAS 样本中得到了复制。在途径分析中,显著的 EV-miRNAs 表明它们可以靶向调节呼吸细胞免疫、肺部炎症反应和气道结构完整性的生物学途径。血浆 EV-miRNA 可能是亚临床肺损伤的一种强大的生物标志物,有助于早期识别和治疗有发展为明显肺部疾病风险的患者。